Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022.
Deciphering which businesses can sustain their high growth rates is a challenge for even the most seasoned professionals, which is why we started StockStory. Keeping that in mind, here are two growth stocks where the best is yet to come and one facing an uphill battle.
One Growth Stock to Sell:
CECO Environmental (CECO)
One-Year Revenue Growth: +37.6%
With roots dating back to 1869 and a focus on creating cleaner industrial operations, CECO Environmental (NASDAQ:CECO) provides technology and expertise that helps industrial companies reduce emissions, treat water, and improve energy efficiency across various sectors.
Why Do We Think Twice About CECO?
- Smaller revenue base of $903.2 million means it hasn’t achieved the economies of scale that some industry juggernauts enjoy (but also enables it to grow faster if it executes properly)
- Costs have risen faster than its revenue over the last five years, causing its adjusted operating margin to decline by 4.8 percentage points
- High net-debt-to-EBITDA ratio of 6× increases the risk of forced asset sales or dilutive financing if operational performance weakens
At $65.87 per share, CECO Environmental trades at 24.7x forward P/E. Read our free research report to see why you should think twice about including CECO in your portfolio.
Two Growth Stocks to Watch:
Hims & Hers Health (HIMS)
One-Year Revenue Growth: +28%
Originally launched with a focus on stigmatized conditions like hair loss and sexual health, Hims & Hers Health (NYSE:HIMS) operates a consumer-focused telehealth platform that connects patients with healthcare providers for prescriptions and wellness products.
Why Could HIMS Be a Winner?
- Average customer growth of 25.1% over the past two years demonstrates success in acquiring new clients that could increase their spending in the future
- Free cash flow margin increased by 15.9 percentage points over the last five years, giving the company more capital to invest or return to shareholders
- Returns on capital are increasing as management’s prior bets are starting to bear fruit
Hims & Hers Health’s stock price of $30.94 implies a valuation ratio of 22.1x forward P/E. Is now the time to initiate a position? Find out in our full research report, it’s free.
DHT Holdings (DHT)
One-Year Revenue Growth: +72.9%
With each vessel capable of carrying roughly 2 million barrels of oil—enough to fill about 125 Olympic swimming pools—DHT Holdings (NYSE:DHT) operates very large crude carriers that transport crude oil across international routes for energy companies and traders.
Why Are We Fans of DHT?
- Market share has increased this cycle as its 6.4% annual revenue growth over the last ten years was exceptional
- EBITDA profits and efficiency rose over the last five years as it benefited from some fixed cost leverage
- DHT is a free cash flow machine with the flexibility to invest in growth initiatives or return capital to shareholders
DHT Holdings is trading at $24.63 per share, or 8x forward P/E. Is now a good time to buy? See for yourself in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.